Home › Drug Codes › J Codes › J8522 · XELODA
Updated July 1st, 2026

XELODA J Code: J8522

Capecitabine, oral, 50 mg

Login to unlock all benchmarks

Q4 2026 Medicare Payment Limit for J8522, effective October 1, 2026: $0.029 per HCPCS billing unit, down 63.8% from $0.08. From CMS's final file.

?
Medicare Payment Limit ?
$0.08
/ HCPCS billing unit · Q3 2026
APC Payment Limit ?
$0.08
/ HCPCS billing unit · APC 0804
ASP ?
$•••.••
Login to view
WAC · AWP ?
$•••.••
Login to view
NDCs Crosswalked ?
37
View NDC crosswalk →

Drug & Product Overview

HCPCS Descriptor Capecitabine, oral, 50 mg
HCPCS Added Date October 1, 2024
Manufacturer Multiple Manufacturers
Route of Administration Oral
Generic Status Multi-Source; Generic
Dosage Form Not Available | Tablet | Tablet, Film Coated

About XELODA

Xeloda is a medication aligned to the HCPCS J Code: J8522 for billing, pricing, and reimbursement purposes in the United States. Classified under Oncology, it is administered via the oral route and manufactured by multiple companies.

According to CMS Drug Use Information: Capecitabine is used to treat certain types of cancer (such as breast, colon, rectal, stomach, esophageal, pancreatic cancer). It works by slowing or stopping the growth of cancer cells.

Disclaimer: This is a summary and does not contain all possible information about this product. For complete information about this product or your specific health needs, ask your healthcare professional.

NDC Code Information

Based on publicly available CMS files. Showing 5 of 37 NDCs — log in for the full crosswalk.

NDC Code Drug Manufacturer Billing Units / Pkg Package Size
00004-1100-20 Xeloda Genentech, Inc. 180 150 MG
00093-7473-06 Capecitabine Teva Pharmaceuticals USA, Inc. 180 150 MG
16714-0467-01 Capecitabine Northstar RxLLC 180 150 MG
16729-0072-12 Capecitabine Accord Healthcare Inc. 180 150 MG
55111-0496-60 capecitabine Dr. Reddy's Laboratories Limited 180 150 MG
•••••-••••-•• Log in to view XELODA
XELODA
XELODA
Login to view 32 more NDC packages View pricing, complete NDC-to-HCPCS alignments, and package details.
Login →

XELODA Pricing & Reimbursement

J8522 Private Payer Reimbursement
$0.04 / HCPCS unit as of Jan 2026

National median reimbursement across major commercial payers.

Create an account on PayerPrice for more information →
UnitedHealthcare, BlueCross BlueShield, Aetna, Cigna

Historical Graphing and Billing Calculator

per HCPCS unit
As of Q3 2026

XELODA Claims Performance

Claims from Jan 2026 – Aug 2026
Claim Denial Rate 88.89%
Avg. Days to File 42.8days
Avg. Days to Pay 0.0days

Real-world claims performance from FocalPoint, OnPoint Oncology's reimbursement analytics platform, with claims data accrued at the clearing house level.

Explore J8522 claims analytics on FocalPoint →
OnPoint Oncology

XELODA CPT Administration Codes

The below list of CPT codes is intended for informational purposes only and may not be exhaustive. CPT® codes and descriptions are copyright American Medical Association (AMA). All rights reserved.

CPT Code Description
96365 Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour
96366 Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); each additional hour (List separately in addition to code for primary procedure)
Not on the CMS JW / JZ list

This product is new and does not yet appear on the CMS list of HCPCS pertaining to single-dose containers. Wastage billing guide →

XELODA Clinical Information

Indications and drug classification.

Treated Diseases & Conditions

This list of indications is not exhaustive and may be subject to errors. The information on BuyandBill.com is intended for informational purposes only and should not be used for medical advice.

Advanced or Metastatic Breast Cancer Breast Cancer Colon Cancer Colorectal Cancer Gastric or Gastroesophageal Junction Adenocarcinoma Gastric, Esophageal, or Gastroesophageal Junction Cancer HER2-Overexpressing Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma HER2-overexpressing Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Locally Advanced Rectal Cancer Pancreatic Adenocarcinoma Rectal Cancer Unresectable or Metastatic Colorectal Cancer Unresectable or Metastatic Gastric, Esophageal, or Gastroesophageal Junction Cancer
Drug Class
Nucleic Acid Synthesis Inhibitors [MoA]Nucleoside Metabolic Inhibitor [EPC]

Login for BuyandBill.com Analytics

Unlock deeper insights with BuyandBill’s Comparative Report!

  • Compare ASP, WAC, and AWP across drugs.
  • Visualize Drug Price Movement Over Time
  • Tailor reports to drug class, manufacturer, or HCPCS Code.
  • Compare Biosimilar and 505(b)(2) products.
Access Full Report →

Frequently Asked Questions

Is there an available XELODA billing and coding guide?
Billing and coding information for XELODA can be found through Genentech, Inc. Visit Here →
Are there any available XELODA patient assistance programs?
XELODA patient assistance information can be found through Genentech, Inc. Visit Here →
Where can I find XELODA prescribing information?
XELODA prescribing information can be found at the link below. Visit Here →
Where can I find XELODA side effect information?
Information on the side effects of XELODA can be found at the below link.
Does billing XELODA require JZ/JW wastage modifiers?
CMS does not include XELODA (J8522) on its list of HCPCS pertaining to single-dose containers. Per CMS guidelines, the JZ/JW wastage modifiers may not apply when billing J8522. For more information, visit the link below.

About BuyandBill.com:

The BuyandBill.com team is dedicated to delivering high-quality coding and billing information for office-administered drugs. We continuously research HCPCS-coded medications to expand our resources and ensure data accuracy. Manufacturers: click here to sponsor your medication, and we will ensure the most accurate and detailed information is displayed.

Related Drug Codes

Explore billing, coding, and pricing for drugs related to XELODA.

Q5114OGIVRIInjection, trastuzumab-dkst, biosimilar, (ogivri), 10 mgBiocon Biologics IncAdded July 1, 2019Q5146HERCESSIInjection, trastuzumab-strf (hercessi), biosimilar, 10 mgAccordAdded January 1, 2025J9184AVGEMSIInjection, gemcitabine hydrochloride (avyxa), 200 mgAvyxa PharmaAdded January 1, 2026J9190FLUOROURACILInjection, fluorouracil, 500 mgMultiple ManufacturersAdded January 1, 1984J9191FavlyxaInjection, fluorouracil (avyxa), 10 mgAvyxa PharmaAdded October 1, 2026J9192FluorouracilInjection, fluorouracil, 10 mgMultiple ManufacturersAdded October 1, 2026J9196GEMCITABINEInjection, gemcitabine hydrochloride (accord), not therapeutically equivalent to j9201, 200 mgAccordAdded April 1, 2023J9201GEMCITABINEInjection, gemcitabine hydrochloride, not otherwise specified, 200 mgMultiple ManufacturersAdded January 1, 1998J9000ADRIAMYCINInjection, doxorubicin hydrochloride, 10 mgMultiple ManufacturersAdded January 1, 1984J9171DOCETAXELInjection, docetaxel, 1 mgMultiple ManufacturersAdded January 1, 2010